Blood Biomarkers Predict Survival Outcomes in Patients with Hepatitis B Virus-Induced Hepatocellular Carcinoma Treated with PD-1 Inhibitors
- PMID: 36033384
- PMCID: PMC9402369
- DOI: 10.1155/2022/3781109
Blood Biomarkers Predict Survival Outcomes in Patients with Hepatitis B Virus-Induced Hepatocellular Carcinoma Treated with PD-1 Inhibitors
Abstract
Purpose: To investigate the prognostic value of blood markers in patients with hepatitis B virus (HBV)-induced hepatocellular carcinoma (HCC) treated with PD-1 inhibitors. Patients and Methods. We retrospectively collected and analyzed the clinicopathological data of 110 HBV-induced HCC patients treated with PD-1 inhibitors. Progression-free survival (PFS) and overall survival (OS) were scrutinized using Kaplan-Meier analysis and the log-rank test, and all potential risk factors were analyzed with univariate and multivariate Cox regression analyses.
Results: The mean OS and PFS were 6.5 and 5.5 months, respectively. According to Kaplan-Meier survival curves, elevated systemic immune-inflammation index (SII), platelet-to-lymphocyte ratio (PLR), and neutrophil-to-lymphocyte ratio (NLR) correlated with decreased OS and PFS (all P < 0.05), and low lymphocyte-to-monocyte ratio (LMR) correlated with decreased PFS and OS (all P < 0.05). Per multivariate Cox regression analyses, SII, PLR, and portal vein tumor thrombus (PVTT) correlated independently with PFS (all P < 0.05), whereas SII, PLR, NLR, and portal vein tumor thrombus (PVTT) correlated with OS (all P < 0.05).
Conclusion: SII, PLR, and PVTT predicted OS and PFS in HCC patients who received PD-1 inhibitors and, therefore, could be useful predictors for risk stratification and individualized therapeutic decision-making for patients with HBV-induced HCC treated with PD-1 inhibitors.
Copyright © 2022 Rui Huang et al.
Conflict of interest statement
The authors report no conflicts of interest in this work.
Figures



Similar articles
-
Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.J Clin Lab Anal. 2019 Oct;33(8):e22964. doi: 10.1002/jcla.22964. Epub 2019 Jul 8. J Clin Lab Anal. 2019. PMID: 31282096 Free PMC article.
-
Predictive value of immunotherapy-induced inflammation indexes: dynamic changes in patients with nasopharyngeal carcinoma receiving immune checkpoint inhibitors.Ann Med. 2023;55(2):2280002. doi: 10.1080/07853890.2023.2280002. Epub 2023 Dec 8. Ann Med. 2023. PMID: 38065623 Free PMC article.
-
Prognostic significance of preoperative aspartate aminotransferase to neutrophil ratio index in patients with hepatocellular carcinoma after hepatic resection.Oncotarget. 2016 Nov 1;7(44):72276-72289. doi: 10.18632/oncotarget.10848. Oncotarget. 2016. PMID: 27472390 Free PMC article.
-
Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.Int Immunopharmacol. 2020 Aug;85:106677. doi: 10.1016/j.intimp.2020.106677. Epub 2020 Jun 9. Int Immunopharmacol. 2020. PMID: 32531712
-
Prognostic value of preoperative lymphocyte-related systemic inflammatory biomarkers in upper tract urothelial carcinoma patients treated with radical nephroureterectomy: a systematic review and meta-analysis.World J Surg Oncol. 2020 Oct 23;18(1):273. doi: 10.1186/s12957-020-02048-7. World J Surg Oncol. 2020. PMID: 33097052 Free PMC article.
Cited by
-
Predictive Biomarkers for Immune-Checkpoint Inhibitor Treatment Response in Patients with Hepatocellular Carcinoma.Int J Mol Sci. 2023 Apr 21;24(8):7640. doi: 10.3390/ijms24087640. Int J Mol Sci. 2023. PMID: 37108802 Free PMC article. Review.
-
Predictive Biomarkers of Immune Checkpoint Inhibitor-Based Mono- and Combination Therapies for Hepatocellular Carcinoma.J Cancer. 2024 Jan 1;15(2):484-493. doi: 10.7150/jca.90128. eCollection 2024. J Cancer. 2024. PMID: 38169551 Free PMC article. Review.
-
Prognostic and clinicopathological significance of Systemic Immune-Inflammation Index in cancer patients receiving immune checkpoint inhibitors: a meta-analysis.Ann Med. 2023 Dec;55(1):808-819. doi: 10.1080/07853890.2023.2181983. Ann Med. 2023. PMID: 36892953 Free PMC article.
-
High Neutrophil-to-Lymphocyte Ratio Facilitates Cancer Growth-Currently Marketed Drugs Tadalafil, Isotretinoin, Colchicine, and Omega-3 to Reduce It: The TICO Regimen.Cancers (Basel). 2022 Oct 10;14(19):4965. doi: 10.3390/cancers14194965. Cancers (Basel). 2022. PMID: 36230888 Free PMC article.
-
Exploring potential predictive biomarkers through historical perspectives on the evolution of systemic therapies into the emergence of neoadjuvant therapy for the treatment of hepatocellular carcinoma.Front Oncol. 2024 Jun 27;14:1429919. doi: 10.3389/fonc.2024.1429919. eCollection 2024. Front Oncol. 2024. PMID: 38993637 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical